A quantitative assessment of epidemiological parameters required to investigate COVID-19 burden.
Contact tracing data
Disease burden
Epidemiological parameters
Risk outcomes
SARS-CoV-2
Journal
Epidemics
ISSN: 1878-0067
Titre abrégé: Epidemics
Pays: Netherlands
ID NLM: 101484711
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
10
05
2021
revised:
07
10
2021
accepted:
12
11
2021
pubmed:
27
11
2021
medline:
21
12
2021
entrez:
26
11
2021
Statut:
ppublish
Résumé
Solid estimates describing the clinical course of SARS-CoV-2 infections are still lacking due to under-ascertainment of asymptomatic and mild-disease cases. In this work, we quantify age-specific probabilities of transitions between stages defining the natural history of SARS-CoV-2 infection from 1965 SARS-CoV-2 positive individuals identified in Italy between March and April 2020 among contacts of confirmed cases. Infected contacts of cases were confirmed via RT-PCR tests as part of contact tracing activities or retrospectively via IgG serological tests and followed-up for symptoms and clinical outcomes. In addition, we provide estimates of time intervals between key events defining the clinical progression of cases as obtained from a larger sample, consisting of 95,371 infections ascertained between February and July 2020. We found that being older than 60 years of age was associated with a 39.9% (95%CI: 36.2-43.6%) likelihood of developing respiratory symptoms or fever ≥ 37.5 °C after SARS-CoV-2 infection; the 22.3% (95%CI: 19.3-25.6%) of the infections in this age group required hospital care and the 1% (95%CI: 0.4-2.1%) were admitted to an intensive care unit (ICU). The corresponding proportions in individuals younger than 60 years were estimated at 27.9% (95%CI: 25.4-30.4%), 8.8% (95%CI: 7.3-10.5%) and 0.4% (95%CI: 0.1-0.9%), respectively. The infection fatality ratio (IFR) ranged from 0.2% (95%CI: 0.0-0.6%) in individuals younger than 60 years to 12.3% (95%CI: 6.9-19.7%) for those aged 80 years or more; the case fatality ratio (CFR) in these two age classes was 0.6% (95%CI: 0.1-2%) and 19.2% (95%CI: 10.9-30.1%), respectively. The median length of stay in hospital was 10 (IQR: 3-21) days; the length of stay in ICU was 11 (IQR: 6-19) days. The obtained estimates provide insights into the epidemiology of COVID-19 and could be instrumental to refine mathematical modeling work supporting public health decisions.
Identifiants
pubmed: 34826786
pii: S1755-4365(21)00074-8
doi: 10.1016/j.epidem.2021.100530
pmc: PMC8595250
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100530Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Nat Commun. 2020 Oct 27;11(1):5411
pubmed: 33110070
PLoS Comput Biol. 2020 Oct 15;16(10):e1008388
pubmed: 33057438
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
Lancet Infect Dis. 2020 May;20(5):553-558
pubmed: 32171059
Emerg Infect Dis. 2020 Nov;26(11):e1-e14
pubmed: 32917290
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Epidemics. 2021 Dec;37:100528
pubmed: 34814093
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33080168
Euro Surveill. 2020 Dec;25(49):
pubmed: 33303064
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Int J Environ Res Public Health. 2020 Oct 17;17(20):
pubmed: 33080869
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet. 2003 May 24;361(9371):1767-72
pubmed: 12781535
Am J Epidemiol. 2022 Jan 1;191(1):137-146
pubmed: 34652416
Elife. 2020 Aug 24;9:
pubmed: 32831176
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Clin Microbiol Infect. 2021 Apr;27(4):633.e1-633.e7
pubmed: 33253941
PLoS Comput Biol. 2020 Jul 2;16(7):e1008031
pubmed: 32614817
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
Int J Infect Dis. 2020 Nov;100:112-116
pubmed: 32891737
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
Nat Rev Phys. 2020;2(6):279-281
pubmed: 33728401
Lancet Infect Dis. 2021 Apr;21(4):e69-e70
pubmed: 32679085
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
BMC Med. 2021 Apr 9;19(1):89
pubmed: 33832497
JAMA Netw Open. 2021 Mar 1;4(3):e211085
pubmed: 33688964
J Med Internet Res. 2020 Oct 12;22(10):e19994
pubmed: 33001833
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
Lancet Infect Dis. 2021 Jan;21(1):27-28
pubmed: 32473661
Euro Surveill. 2020 Aug;25(31):
pubmed: 32762797
J Clin Med. 2020 Mar 31;9(4):
pubmed: 32244365
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Proc Natl Acad Sci U S A. 2021 Jan 26;118(4):
pubmed: 33414277
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Nature. 2021 May;593(7858):266-269
pubmed: 33767447